Tirzepatide cost in 2026: compounded, brand and by provider
Compounded tirzepatide costs more than compounded semaglutide, and the gap is structural: fewer FDA-registered facilities can produce injectable-grade tirzepatide, which lifts the price floor across every legitimate provider.
As of July 15, 2026, compounded tirzepatide runs roughly $199–$297 per month for standard programs, with MEDVi reporting the lowest published self-pay price near $199/month and Mochi at $278/month all-in ($199 medication + $79 required membership). Brand Zepbound lists near $1,086/month, with LillyDirect self-pay vials from $299. All competitor figures are Provider Reported; only prices we capture first-party are labeled Verified.
Why tirzepatide costs more than semaglutide
Tirzepatide is a dual GIP and GLP-1 receptor agonist, a more complex molecule than semaglutide, and fewer FDA-registered outsourcing facilities can produce injectable-grade tirzepatide active ingredient. That supply constraint raises the cost floor across all legitimate 503A and 503B providers, which is why a compounded tirzepatide program almost always costs more than the same provider’s compounded semaglutide. Industry reporting flags sustained maintenance pricing below about $200 per month as a red flag for bait-and-switch pricing or non-legitimate sourcing.
Compounded tirzepatide price by provider
| Provider | Medication | Effective all-in | Membership | Evidence status |
|---|---|---|---|---|
| MEDVi | $199 (starting) | $199 | Sometimes | Verification Pending |
| Eden Health | $249–296 | $249–296 | None (bundled) | Verification Pending |
| Mochi Health | $199 | $278 | $79 (required) | Provider Reported |
| Henry Meds | $297 (m2m) | $297–549 | None | Provider Reported |
Sources: provider pricing pages, Forbes Health, U.S. News, and market reporting captured July 2026. Ledger records CMP-*-TIRZ-*. See our affordability methodology.
Brand tirzepatide: Zepbound and Mounjaro
Brand tirzepatide is sold as Zepbound (approved for chronic weight management and obstructive sleep apnea) and Mounjaro (approved for type 2 diabetes). List price is near $1,086 per month, but Eli Lilly’s LillyDirect self-pay vials start around $299 per month. Medicare does not cover Zepbound for weight loss under the current statutory exclusion, though it covers Mounjaro for type 2 diabetes; commercial coverage of Zepbound for weight loss reaches roughly 30–40 percent of large employer plans, almost always with prior authorization.
Compounded versus brand: the trade-off
Compounded tirzepatide is far cheaper than brand at the pharmacy counter, but it is not FDA-approved and carries none of the SURMOUNT trial evidence that backs Zepbound. After the 2025 tirzepatide shortage resolution, routine compounding of copies is restricted to patient-specific circumstances with a documented clinical difference, the same framework that governs compounded semaglutide. Weigh the price gap against the loss of FDA review and trial-backed evidence, and confirm any program dispenses base tirzepatide through a named, state-licensed pharmacy.
Limitations
Most competitor figures here are Provider Reported or Verification Pending, not first-party Verified, because tier-1 provider sites often render pricing client-side or block automated retrieval. Prices shift with promotions, dose strength, and commitment; always confirm the current published price and total mandatory fees on the provider’s own site before enrolling.
Sources
- Forbes Health — Henry Meds review. forbes.com/health
- Evidence ledger records CMP-*-TIRZ-*, BRAND-ZEP-001. evidence-ledger.csv
- Provider pricing and market reporting captured July 2026.
Sources: FDA — human drug compounding and GLP-1 status; clinical evidence via NEJM. Pricing captured July 2026; see evidence ledger. Last reviewed July 2026.